AbbVie Shares Look Set to Tackle the Century Level

Here's the case for an ABBV breakout into triple-digit territory

Editor-in-Chief
Dec 29, 2017 at 2:59 PM
facebook twitter linkedin


The consolidation pattern in the $90-$95 area over the past three months by drug stock AbbVie (ABBV) appears very similar to that of June through July (in the $70-$75 area), which was followed by a rapid 30% rally.

Reasons to believe the most recent consolidation has been completed include: support that manifested at the 50-day moving average on a pullback earlier this month; ongoing "micro-moves" to all-time highs this month after the Oct. 20 peak had stood unchallenged for six weeks; and renewed 20-day Relative Momentum Index (RMI) buy signals following recent short-term pullbacks (see chart).

Moves past the $100 century mark can be a challenge, and this is also the site of triple the initial lows after the ABBV spin-off from Abbott Labs. But the robust technicals (including a strong pattern of higher lows on pullbacks) is likely to resolve with another burst to the upside. Plus, there is plenty of room for a boost in call option speculation to drive the shares past resistance, with call open interest currently in the 16th percentile (per Trade-Alert) and less than half the peak levels of May 2017.

Our recommended call option triples on a move to the $110 area -- site of double the October 2016 low. In the meantime, we expect pullbacks to be contained at the rising 50-day moving average.

abbv sm daily price chart 1222


Subscribers to Schaeffer's Weekend Player options recommendation service received this ABBV commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters -- straight from Bernie's trading desk. Learn more about why Weekend Player is one of our most popular options trading services.

Grab your FREE Eternal Contrarian report!


 




 
Special Offers from Schaeffer's Trading Partners